Alpha-9 Oncology Alpha-9 develops radiopharmaceuticals for solid tumors, using iterative molecular design to optimize binders, linkers, chelators, and radioisotopes.
Products & media
An investigational actinium-225 radiotherapeutic targeting GRPR, being evaluated in Phase 1 for breast cancer and other solid tumors.
An investigational gallium-68 imaging agent that identifies GRPR-positive tumors to support patient selection for Alpha-9’s radiotherapeutic studies.
An investigational lutetium-177 radiotherapeutic targeting GRPR, being evaluated in Phase 1 for breast cancer and other solid tumors.
An investigational actinium-225 radiotherapeutic targeting NTSR1 for pancreatic, colorectal, and other cancers in Alpha-9’s development pipeline.
An investigational gallium-68 imaging agent paired with Alpha-9’s NTSR1 radiotherapeutic program for pancreatic, colorectal, and other cancers.
Team
Jobs
See all jobs for Alpha-9 Oncology here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels